Molecular imaging of human tumor cells that naturally overexpress type 2 cannabinoid receptors using a quinolone-based near-infrared fluorescent probe

Journal of Biomedical Optics

Volumn 19, Issue 7, 2014, Pages

  Wu, Zhiyuan ^a,b   Shao, Pin ^a   Zhang, Shaojuan ^a,c   Ling, Xiaoxi ^a   Bai, Mingfeng ^a,d,e  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^c XI'AN JIAOTONG UNIVERSITY   (China)

^d UNIVERSITY OF PITTSBURGH   (United States)

^e University of Pittsburgh   (United States)

Author keywords

fluorescence imaging.; leukemia; near infrared; optical imaging

Indexed keywords

DIAGNOSIS; FLUORESCENCE; INFRARED DEVICES; MOLECULAR IMAGING; PROBES; TUMORS;

FLUORESCENCE IMAGING; LEUKEMIA; NEAR INFRARED; OPTICAL IMAGING;

DISEASES;

CANNABINOID 2 RECEPTOR; FLUORESCENT DYE; MOLECULAR PROBE; QUINOLONE DERIVATIVE; TUMOR MARKER;

ANALYSIS; CHEMISTRY; GENETICS; HUMAN; JURKAT CELL LINE; METABOLISM; MOLECULAR IMAGING; MOLECULAR PROBE; PROCEDURES;

FLUORESCENT DYES; HUMANS; JURKAT CELLS; MOLECULAR IMAGING; MOLECULAR PROBES; QUINOLONES; RECEPTOR, CANNABINOID, CB2; TUMOR MARKERS, BIOLOGICAL;

EID: 84925545898     PISSN: 10833668     EISSN: 15602281     Source Type: Journal    
DOI: 10.1117/1.JBO.19.7.076016     Document Type: Article

References (53)

1. T. Sugiura et al., "Evidence for the involvement of the cannabinoid CB2 receptor and its endogenous ligand 2-arachidonoylglycerol in 12-Otetradecanoylphorbol-13-acetate-induced acute inflammation in mouse ear," J. Biol. Chem. 280(18), 18488-18497 (2005). (Pubitemid 41389098)
2. H. Iwamura et al., "In vitro and in vivo pharmacological characterization of JTE907, a novel selective ligand for cannabinoid CB2 receptor," J. Pharmacol. Exp. Ther. 296(2), 420-425 (2001). (Pubitemid 32112468)
3. A. Makriyannis et al., "Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS," Proc. Natl. Acad. Sci. USA 100(18), 10529-10533 (2003). (Pubitemid 37071912)
4. M. Karsak et al., "The cannabinoid CB2 receptor: a potential target for the diagnosis and treatment of osteoporosis," J. Bone Miner. Res. 19(S1), S383-S383 (2004).
5. R. G. Pertwee, "Cannabinoids and multiple sclerosis," Mol. Neurobiol. 36(1), 45-59 (2007). (Pubitemid 351360354)
6. M. Morales and A. Bonci, "Hooking CB2 receptor into drug abuse?," Nat. Med. 18(4), 504-505 (2012).
7. I. Gamaleddin et al., "Effects of a selective cannabinoid CB2 agonist and antagonist on intravenous nicotine self administration and reinstatement of nicotine seeking," Plos One 7(1), e29900 (2012).
8. A. Ortega-Alvaro et al., "Deletion of CB2 cannabinoid receptor induces schizophrenia-related behaviors in mice," Neuropsychopharmacology 36(7), 1489-1504 (2011).
9. M. S. Garcia-Gutierrez and J. Manzanares, "Overexpression of CB2 cannabinoid receptors decreased vulnerability to anxiety and impaired anxiolytic action of alprazolam in mice," J. Psychopharmacol. 25(1), 111-120 (2011).
10. M. S. Garcia-Gutierrez et al., "Chronic blockade of cannabinoid CB2 receptors induces anxiolytic-like actions associated with alterations in GABA(A) receptors," Br. J. Pharmacol. 165(4), 951-964 (2012).
11. K. A. Jenkin et al., "Endocannabinoids and the renal proximal tubule: an emerging role in diabetic nephropathy," Int. J. Biochem. Cell Biol. 44(11), 2028-2031 (2012).
12. J. Agudo et al., "Deficiency of CB2 cannabinoid receptor in mice improves insulin sensitivity but increases food intake and obesity with age," Diabetologia 53(12), 2629-2640 (2010).
13. C. Gonzalez et al., "Cannabinoid/agonist WIN 55,212-2 reduces cardiac ischaemia-reperfusion injury in Zucker diabetic fatty rats: role of CB2 receptors and iNOS/eNOS," Diabetes-Metab. Res. 27(4), 331-340 (2011).
14. S. Steffens and P. Pacher, "Targeting cannabinoid receptor CB2 in cardiovascular disorders: promises and controversies," Br. J. Pharmacol. 167(2), 313-323 (2012).
15. G. Velasco et al., "Cannabinoids and gliomas," Mol. Neurobiol. 36(1), 60-67 (2007). (Pubitemid 351360351)
16. P. Pacher, S. Batkai, and G. Kunos, "The endocannabinoid system as an emerging target of pharmacotherapy," Pharmacol. Rev. 58(3), 389-462 (2006). (Pubitemid 44394908)
17. Z. Qamri et al., "Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer," Mol. Cancer Ther. 8(11), 3117-3129 (2009).
18. M. M. Caffarel et al., "Cannabinoids: a new hope for breast cancer therapy?," Cancer Treat Rev. 38(7), 911-918 (2012).
19. M. M. Caffarell et al., "Antitumoural effect of cannabinoids in an animal model of breast cancer," EJC Suppl. 6(9), 18-18 (2008).
20. N. Olea-Herrero et al., "Inhibition of human tumour prostate PC-3 cell growth by cannabinoids R(+)-Methanandamide and JWH-015: involvement of CB2," Br. J. Cancer 101(6), 940-950 (2009).
21. S. Sarfaraz et al., "Cannabinoid receptor as a novel target for the treatment of prostate cancer," Cancer Res. 65(5), 1635-1641 (2005). (Pubitemid 40478586)
22. C. Sanchez et al., "Inhibition of glioma growth in vivo by selective activation of the CB2 cannabinoid receptor," Cancer Res. 61(15), 5784-5789 (2001). (Pubitemid 32769095)
23. F. Cianchi et al., "Cannabinoid Receptor activation induces apoptosis through tumor necrosis factor alpha-mediated ceramide de novo synthesis in colon cancer cells," Clin. Cancer Res. 14(23), 7691-7700 (2008).
24. A. Preet et al., "Cannabinoid receptors, CB1 and CB2, as novel targets for inhibition of non-small cell lung cancer growth and metastasis," Cancer Prev. Res. 4(1), 65-75 (2011).
25. Y. Shi et al., "Cannabinoid 2 receptor induction by IL-12 and its potential as a therapeutic target for the treatment of anaplastic thyroid carcinoma," Cancer Gene Ther. 15(2), 101-107 (2008).
26. R. J. McKallip et al., "Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease," Blood 100(2), 627-634 (2002). (Pubitemid 34761128)
27. C. Blazquez et al., "Cannabinoid receptors as novel targets for the treatment of melanoma," Faseb. J. 20(14), 2633-2635 (2006).
28. A. Carracedo et al., "Cannabinoids induce apoptosis of pancreatic tumor cells via endoplasmic reticulum stress-related genes," Cancer Res. 66(13), 6748-6755 (2006). (Pubitemid 44085633)
29. D. Vara et al., "Anti-tumoral action of cannabinoids on hepatocellular carcinoma: role of AMPK-dependent activation of autophagy," Cell Death Differ. 18(7), 1099-1111 (2011).
30. B. G. Ramirez et al., "Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation," J. Neurosci. 25(8), 1904-1913 (2005). (Pubitemid 40289395)
31. E. L. Scotter, M. E. Abood, and M. Glass, "The endocannabinoid system as a target for the treatment of neurodegenerative disease," Br. J. Pharmacol. 160(3), 480-498 (2010).
32. E. Torres et al., "Evidence that MDMA ('ecstasy') increases cannabinoid CB2 receptor expression in microglial cells: role in the neuroinflammatory response in rat brain," J. Neurochem. 113(1), 67-78 (2010).
33. N. Evens and G. M. Bormans, "Non-invasive imaging of the type 2 cannabinoid receptor, focus on positron emission tomography," Curr. Top. Med. Chem. 10(15), 1527-1543 (2010).
34. T. F. Massoud and S. S. Gambhir, "Molecular imaging in living subjects: seeing fundamental biological processes in a new light," Gene Dev. 17(5), 545-580 (2003). (Pubitemid 36307540)
35. J. V. Frangioni, "In vivo near-infrared fluorescence imaging," Curr. Opin. Chem. Biol. 7(5), 626-634 (2003). (Pubitemid 37315800)
36. L. M. A. Crane et al., "Intraoperative near-infrared fluorescence imaging for sentinel lymph node detection in vulvar cancer: first clinical results," Gynecol. Oncol. 120(2), 291-295 (2011).
37. G. M. van Dam et al., "Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-alpha targeting: first in-human results," Nat. Med. 17(10), 1315-U1202 (2011).
38. A. G. T. T. van Scheltinga et al., "Intraoperative near-infrared fluorescence tumor imaging with vascular endothelial growth factor and human epidermal growth factor receptor 2 targeting antibodies," J. Nucl. Med. 52(11), 1778-1785 (2011).
39. R. Atreya, M. J. Waldner, and M. F. Neurath, "Molecular imaging: interaction between basic and clinical science," Gastroenterol. Clin. North. Am. 39(4), 911-922 (2010).
40. H. K. Roy et al., "Colonoscopy and optical biopsy: bridging technological advances to clinical practice," Gastroenterology 140(7), 1863-1867 (2011).
41. M. Bai and D. J. Bornhop, "Recent advances in receptor-targeted fluorescent probes for in vivo cancer imaging," Curr. Med. Chem. 19(28), 4742-4758 (2012).
42. M. F. Bai et al., "MBC94, a conjugable ligand for cannabinoid CB2 receptor imaging," Bioconjugate Chem. 19(5), 988-992 (2008).
43. R. G. Pertwee and R. A. Ross, "Cannabinoid receptors and their ligands," Prostaglandins, Leukot. Essent. Fatty Acids 66(2-3), 101-121 (2002). (Pubitemid 34743589)
44. E. Cudaback et al., "The expression level of CB1 and CB2 receptors determines their efficacy at inducing apoptosis in astrocytomas," Plos One 5(1), e8702 (2010).
45. M. Sexton et al., "NIR-mbc94, a fluorescent ligand that binds to endogenous CB(2) receptors and is amenable to high-throughput screening," Chem. Biol. 18(5), 563-568 (2011).
46. S. Zhang, P. Shao, and M. Bai, "In vivo Type 2 cannabinoid receptortargeted tumor optical imaging using a near infrared fluorescent probe," Bioconjug. Chem. 24(11), 1907-1916 (2013).
47. S. Pasquini et al., "Investigations on the 4-quinolone-3-carboxylic acid motif. 4. identification of new potent and selective ligands for the cannabinoid type 2 receptor with diverse substitution patterns and antihyperalgesic effects in mice," J. Med. Chem. 54(15), 5444-5453 (2011).
48. S. Pasquini et al., "Investigations on the 4-Quinolone-3-carboxylic acid motif. 3. Synthesis, structure-affinity relationships, and pharmacological characterization of 6-substituted 4-quinolone-3-carboxamides as highly selective cannabinoid-2 receptor ligands," J. Med. Chem. 53(16), 5915-5928 (2010).
49. S. Pasquini et al., "Investigations on the 4-quinolone-3-carboxylic acid motif. 2. Synthesis and structure-activity relationship of potent and selective cannabinoid-2 receptor agonists endowed with analgesic activity in vivo," J. Med. Chem. 51(16), 5075-5084 (2008).
50. B. Schafer et al., "Preparation of semisynthetic lipoproteins with fluorescent cholesterol anchor and their introduction to the cell membrane with minimal disruption of the membrane," Bioconjug. Chem. 24(10), 1684-1697 (2013).
51. R. C. Benson and H. A. Kues, "Fluorescence properties of indocyanine green as related to angiography," Phys.Med. Biol. 23(1), 159-163 (1978). (Pubitemid 8271627)
52. Y. Zhang et al., "Imaging tumor angiogenesis in breast cancer experimental lung metastasis with positron emission tomography, near-infrared fluorescence, and bioluminescence," Angiogenesis 16(3), 663-674 (2013).
53. H. S. Choi et al., "Targeted zwitterionic near-infrared fluorophores for improved optical imaging," Nat. Biotechnol. 31(2), 148-153 (2013).